Cullinan Oncology, Inc. announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a programmed death receptor-1 (PD-1) targeted checkpoint inhibitor, in patients with advanced solid tumors.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.78 USD | +2.88% |
|
+1.70% | +64.67% |
Jul. 01 | Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) added to Russell Small Cap Comp Growth Index | CI |
Jun. 02 | Transcript : Cullinan Therapeutics, Inc. - Special Call |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.67% | 940M | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines